NCT04447417View on ClinicalTrials.gov

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

June 17, 2021

Study Completion Date

June 17, 2021

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab SAR231893

Pharmaceutical form:solution for injection Route of administration: subcutaneous

Trial Locations (2)

80206

Investigational Site Number 8400001, Denver

H2X 2V1

Investigational Site Number 1240001, Montreal

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT04447417 - Dupilumab Skin Barrier Function Study in Atopic Dermatitis | Biotech Hunter | Biotech Hunter